Zoetis Inc. News
Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses. The company also offers parasiticides; vaccines; anti-infectives; other pharmaceutical products; dermatology; and medicated feed additives. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products and laboratory; and other non-pharmaceutical products. It markets its products to veterinarians, livestock producers, and pet owners. The company was founded in 1952 and is headquartered in Parsippany, New Jersey.
see moreZoetis Inc. Market News
6d
Zoetis Faces Market Volatility Amidst Revised 2026 Guidance
- Zoetis stock declines following Q1 2026 earnings miss and guidance revision.
13d
Zoetis Faces Competitive Pressures Amidst Market Challenges
Zoetis confronts increased competition and market challenges affecting growth.
18d
Zoetis Faces Legal Challenges Amid Stock Volatility
Zoetis confronts securities lawsuit and stock fluctuations.
18d
Zoetis Faces Legal Scrutiny Amid Stock Volatility and Guidance Revisions
Zoetis under investigation following stock plunge and guidance cut.
19d
Zoetis Reports Q1 2026 Results Amidst Strategic Investments and Pipeline Expansion
Zoetis announces Q1 2026 financials, strategic investments, and pipeline growth.
26 May at 14:56
Zoetis Q1 Weakness Trims Guidance, Splits Analysts
Zoetis reported softer-than-expected Q1 results with adjusted EPS of $1.53 and revenue of roughly $2.3B, prompting a narrowed full-year outlook. U.S. companion-animal softness pressured diagnostics and genetic-testing momentum. Analyst reactions diverged—UBS trimmed to Neutral with a $130 target while Citi initiated Buy at $145—creating near-term volatility for ZTS stock.
19 May at 14:56
Zoetis Plunge: Q1 Miss, Guidance Cut Shocks ZTS
Zoetis shares tumbled after a disappointing Q1 report and reduced 2026 outlook, driven by an 11% drop in U.S. companion-animal sales. International and livestock segments showed strength, while peers in diagnostics outperformed—raising questions about near-term recovery and the impact of Zoetis’s Neogen acquisition.